SUPN — Supernus, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$29.04
Market Cap
$1.69B
52W High
$33.22
52W Low
$21.48
ADV30
3,569,794
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 226,771,000 | 199,753,000 | 22,720,000 | 20,913,000 | 1,397,690,000 | 175,884,000 | 335,212,000 |
| Jun 2026 | 219,058,000 | 185,389,000 | -3,044,000 | -58,371,000 | 1,428,109,000 | 179,953,000 | 396,883,000 |
| Mar 2026 | 207,705,000 | 184,314,000 | -5,941,000 | -2,293,000 | 1,500,725,000 | 184,869,000 | 423,920,000 |
| Dec 2025 | 211,572,000 | 188,565,000 | 13,822,000 | -4,105,000 | 1,452,648,000 | 128,448,000 | 390,934,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,911,000
Investing CF
$-14,728,000
Financing CF
$31,509,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$457,212,000
Inventory
$83,924,000
Receivables
$211,656,000
ST Investments
$192,114,000
EBIT TTM
$-119,849,000
Pretax Income TTM
$-123,466,000
Interest Exp TTM
$2,315,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$865,105,984
EBITDA
$116,030,000
Free Cash Flow
$61,711,876
Enterprise Value
$2,117,979,264
Total Cash
$359,459,008
Total Debt
$36,197,000
Shares Out
58,235,716
Trailing EPS
$-0.76
Book Value
$18.24
ROE
-4.2%
ROA
0.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 718,952,000 | -36,864,000 | -38,550,000 | 1,452,648,000 | 390,934,000 | 1,061,714,000 | 47,331,000 |
| Dec 2024 | 661,817,000 | 75,556,000 | 73,865,000 | 1,368,073,000 | 332,340,000 | 1,035,733,000 | 171,951,000 |
| Dec 2023 | 607,521,000 | 13,403,000 | 1,316,000 | 1,277,673,000 | 356,157,000 | 921,516,000 | 111,085,000 |
| Dec 2022 | 667,238,000 | 45,614,000 | 60,711,000 | 1,702,508,000 | 816,304,000 | 886,204,000 | 116,826,000 |
TTM Snapshot
Revenues TTM
$1,331,000,000
NetIncome TTM
$356,000,000
OpCashFlow TTM
—
Assets (Latest)
$1,233,000,000
Forward EPS
$4.17
Max Pain — expiry 2026-12-18
max pain strike: $26.87 · spot: $28.96 · call oi: 2,431 · put oi: 1,683Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc. | $1.69B | $18.78 | — |
| SDGR | Schrodinger, Inc. | $1.68B | $25.66 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.70B | $16.70 | — |
| STOK | Stoke Therapeutics, Inc. | $1.73B | $26.41 | — |
| ZYME | Zymeworks Inc. | $1.78B | $25.84 | — |
News headlines (Yahoo Finance, 1h cache)
Does Supernus Pharmaceuticals (SUPN) Still Trade Below Fair Value On Sales?
2026-11-18 01:16 · Yahoo
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
2026-11-10 13:30 · Yahoo
Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
2026-11-10 06:11 · Yahoo
Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued
2026-11-04 14:18 · Yahoo
Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity
2026-11-03 22:22 · Yahoo
What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?
2026-11-03 19:15 · Yahoo
Why Indivior Pharmaceuticals Stock Topped the Market Today
2026-11-02 22:03 · Yahoo
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
2026-11-02 14:18 · Yahoo
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
2026-11-01 01:55 · Yahoo
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
2026-10-30 22:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.